[go: up one dir, main page]

DK1143976T3 - Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner - Google Patents

Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner

Info

Publication number
DK1143976T3
DK1143976T3 DK00904529T DK00904529T DK1143976T3 DK 1143976 T3 DK1143976 T3 DK 1143976T3 DK 00904529 T DK00904529 T DK 00904529T DK 00904529 T DK00904529 T DK 00904529T DK 1143976 T3 DK1143976 T3 DK 1143976T3
Authority
DK
Denmark
Prior art keywords
beta
d4fc
hiv
fluorocytidine
didehydro
Prior art date
Application number
DK00904529T
Other languages
Danish (da)
English (en)
Inventor
Raymond F Schinazi
John W Mellors
Dennis C Liotta
Jennifer Hammond
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK1143976T3 publication Critical patent/DK1143976T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00904529T 1999-01-22 2000-01-21 Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner DK1143976T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22

Publications (1)

Publication Number Publication Date
DK1143976T3 true DK1143976T3 (da) 2006-09-04

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904529T DK1143976T3 (da) 1999-01-22 2000-01-21 Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner

Country Status (21)

Country Link
EP (1) EP1143976B9 (fr)
JP (1) JP2002535278A (fr)
KR (1) KR100745408B1 (fr)
CN (2) CN1337880A (fr)
AT (1) ATE324894T1 (fr)
AU (1) AU781281B2 (fr)
BR (1) BR0007627A (fr)
CA (1) CA2360039C (fr)
DE (1) DE60027691T2 (fr)
DK (1) DK1143976T3 (fr)
ES (1) ES2263449T3 (fr)
HK (1) HK1040064B (fr)
IL (1) IL144382A (fr)
MX (1) MXPA01007359A (fr)
NO (1) NO323586B1 (fr)
NZ (1) NZ528156A (fr)
PL (1) PL198237B1 (fr)
PT (1) PT1143976E (fr)
RU (1) RU2254133C2 (fr)
WO (1) WO2000043014A2 (fr)
ZA (1) ZA200105971B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311141A (pt) * 2002-06-27 2005-06-07 Medivir Ab Interação sinergìstica de abacavir e alovudine
MXPA06006586A (es) * 2003-12-09 2007-02-21 Pharmasset Inc Metodos de dosificacion para la terapia antiviral con beta-d-2',3'-didesoxi-2',3'-dideshidro-5-fluorocitidina.
US7741334B2 (en) 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
US20060084628A1 (en) * 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU707246A1 (ru) * 1978-09-29 1980-12-23 Институт Биоорганической Химии Ан Белорусской Сср Способ получени хлоргидрата 2"2 -ангидро-1- - -арабинофуранозил - 5-фторцитозина
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
RU2092177C1 (ru) * 1994-08-19 1997-10-10 Научно-производственное объединение "Всероссийский научно-исследовательский институт лекарственных и ароматических растений" Средство, обладающее действием против инфекционных агентов
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Also Published As

Publication number Publication date
WO2000043014A8 (fr) 2001-01-18
CA2360039A1 (fr) 2000-07-27
PT1143976E (pt) 2006-09-29
WO2000043014A2 (fr) 2000-07-27
EP1143976B9 (fr) 2007-02-14
JP2002535278A (ja) 2002-10-22
EP1143976B1 (fr) 2006-05-03
ES2263449T3 (es) 2006-12-16
PL198237B1 (pl) 2008-06-30
AU781281B2 (en) 2005-05-12
WO2000043014A3 (fr) 2000-11-30
CN101219148A (zh) 2008-07-16
DE60027691D1 (de) 2006-06-08
CN1337880A (zh) 2002-02-27
MXPA01007359A (es) 2003-09-22
AU2627000A (en) 2000-08-07
ZA200105971B (en) 2002-10-21
IL144382A (en) 2007-02-11
NZ528156A (en) 2005-03-24
RU2254133C2 (ru) 2005-06-20
EP1143976A2 (fr) 2001-10-17
IL144382A0 (en) 2002-05-23
HK1040064A1 (en) 2002-05-24
DE60027691T2 (de) 2007-04-12
CA2360039C (fr) 2009-11-24
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
NO20013599D0 (no) 2001-07-20
NO20013599L (no) 2001-09-20
KR100745408B1 (ko) 2007-08-02
BR0007627A (pt) 2002-04-09
HK1040064B (en) 2006-07-21
ATE324894T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
TR200002760T2 (tr) HIV engelleyici pirimidin türevleri
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
JP2002528502A5 (fr)
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
WO2006044968A3 (fr) Polytherapie permettant de traiter des infections virales
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
MY105855A (en) Therapeutic nucleotides.
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
DE60025826D1 (de) Pyrazolidinol-verbindungen
EP1731155A3 (fr) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine pour l'utilisation dans le traitement d'une infection par le hiv
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
JOP20220188A1 (ar) عوامل مضادة للفيروسات لعلاج عدوى فيروس نقص المناعة البشرية والوقاية منها
DE60235965D1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
James PMPA--first human results
Prescott Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference
TH45970A (th) การบำบัดรักษา hiv ด้วยการใช้ยาร่วมกันของพีกีเลท อินเตอร์ฟิรอนอัลฟา-ตัวต่อต้าน ccr5